Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Small Cell Lung Cancer: early-phase trial registry
206 of 455 indexed Non-Small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #10 of 28,707 conditions by registered trial count.
455 US clinical trials · 206 currently recruiting · #10 of 28,707 conditions by registered trial count
Non-Small Cell Lung Cancer: 455 US clinical trials tracked, 206 recruiting.
Non-Small Cell Lung Cancer is the subject of 455 registered US clinical trials on ClinicalTrials.gov, 206 of them currently open to new participants. 65 are in Phase 3-4 (later-stage) and 327 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 24 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-cancer
OPEN 206 | RECR 45% | LATE 65 | EARLY 327 | RANK #10 | SPON 24
Volume-matched condition peers
Nearest open-share peer: Gastric Cancer (45% recruiting · 159 trials)
Non-Small Cell Lung Cancer lists 206 open slots (45% of 455 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Small Cell Lung Cancer is recruiting above its size-band peers.
206 of 455 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-Small Cell Lung Cancer trials is spread across many organizations.
AstraZeneca accounts for 24 of 455 trials (5.3%). 242 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-Small Cell Lung Cancer enrolment sits around 105 participants.
Median target enrolment is 105 among the 455 trials that report a genuine target (sentinel values excluded). 212 of those (46.6%) plan for fewer than 100 participants.
-
Non-Small Cell Lung Cancer research is mostly interventional.
414 interventional and 41 observational studies make up this index (91% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
455 total, page 10 of 10
Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
Memorial Sloan Kettering Cancer Center
NCT00577707
Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
Shionogi
NCT00078390
Intratumoral Cisplatin for Resectable NSCLC
University of Vermont
NCT04809103
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
Case Comprehensive Cancer Center
NCT03535363
Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer
University of Wisconsin, Madison
NCT00582634
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 203 |
| Phase 2 | 124 |
| Phase 3 | 62 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Small Cell Lung Cancer page
455 registered trials, 206 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 206 Non-Small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Non-Small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Small Cell Lung Cancer condition card totals 455 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.